A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.
about
Arenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategiesAdvanced vaccine candidates for Lassa feverHost gene targets for novel influenza therapies elucidated by high-throughput RNA interference screensThe yellow fever 17D virus as a platform for new live attenuated vaccinesConstruction and characterization of recombinant flaviviruses bearing insertions between E and NS1 genesT Cell-Mediated Immunity towards Yellow Fever Virus and Useful Animal ModelsVaxCelerate II: rapid development of a self-assembling vaccine for Lassa fever.Comparative analysis of disease pathogenesis and molecular mechanisms of New World and Old World arenavirus infections.Infection, dissemination, and transmission of a West Nile virus green fluorescent protein infectious clone by Culex pipiens quinquefasciatus mosquitoes.Comparative pathogenesis and systems biology for biodefense virus vaccine development.Lassa virus-like particles displaying all major immunological determinants as a vaccine candidate for Lassa hemorrhagic fever.Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in miceVaccination strategies against highly pathogenic arenaviruses: the next steps toward clinical trialsA recombinant vesicular stomatitis virus-based Lassa fever vaccine protects guinea pigs and macaques against challenge with geographically and genetically distinct Lassa viruses.Yellow fever 17D-vectored vaccines expressing Lassa virus GP1 and GP2 glycoproteins provide protection against fatal disease in guinea pigs.Enhanced Efficacy of a Codon-Optimized DNA Vaccine Encoding the Glycoprotein Precursor Gene of Lassa Virus in a Guinea Pig Disease Model When Delivered by Dermal Electroporation.A ML29 reassortant virus protects guinea pigs against a distantly related Nigerian strain of Lassa virus and can provide sterilizing immunityLassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissuesEvaluation of Lassa antiviral compound ST-193 in a guinea pig model.The search for animal models for Lassa fever vaccine developmentVaccine Platforms to Control Arenaviral Hemorrhagic FeversAn attenuated Lassa vaccine in SIV-infected rhesus macaques does not persist or cause arenavirus disease but does elicit Lassa virus-specific immunity.Molecular and immunological characterization of a DNA-launched yellow fever virus 17D infectious clone.Use of viral vectors for the development of vaccines.Safety, immunogenicity, and efficacy of the ML29 reassortant vaccine for Lassa fever in small non-human primates.Current status and future prospects of yellow fever vaccines.Vaccine platforms to control Lassa fever.Differential Immune Responses to New World and Old World Mammalian Arenaviruses.Development of infectious clones for virulent and avirulent pichinde viruses: a model virus to study arenavirus-induced hemorrhagic fevers.Chimpanzee adenoviral vectors as vaccines for outbreak pathogens.A DNA vaccine delivered by dermal electroporation fully protects cynomolgus macaques against Lassa fever.Alphavirus vector-based replicon particles expressing multivalent cross-protective Lassa virus glycoproteins.Baseline mapping of Lassa fever virology, epidemiology and vaccine research and development.Use of a Scalable Replicon-Particle Vaccine to Protect Against Lethal Lassa Virus Infection in the Guinea Pig ModelArenaviruses: Hemorrhagic FeversCurrent research for a vaccine against Lassa hemorrhagic fever virusYellow fever vaccine: past, present and future
P2860
Q24599295-E49C07A7-B649-4A9F-B05D-B44C1555D2FDQ26823627-2D6D6DB1-65B6-4BA3-8BBD-6EC60075663CQ26852062-7781700D-2E05-474B-92ED-B941F105C9E0Q26865102-654664CF-B66C-4452-91E4-2CA0183E296CQ27485041-DAA2C163-BD39-474A-ACB1-264AE47C5DE9Q29994674-65E90852-F6F7-4DDC-BDFD-90E3DD8D06FAQ33723534-80C3F7C5-7B6E-4C2B-8319-9DFEEF9A850BQ33887328-C17EF4C7-525A-4B61-BA0B-1FC3160A3EB7Q33905288-B83AF635-64F6-4564-AD1F-C589FA38AA0FQ33959989-CE1415DF-F764-4AD5-91A6-A0AF0B67D039Q34322342-EA03A6DC-4EE0-4325-AB7F-F9E498AE414BQ34615061-B08801EF-4545-43EA-8A7F-851CD16DF55CQ34671806-7AA48A4D-3B95-49AE-8C27-CB8394DFC640Q35463993-F23688E5-F927-44F2-8E92-7A8BD53F8ED2Q35814851-337115F4-D8A9-49D9-925A-132B6305A238Q35826698-B42E32FE-00BB-417D-BD8A-31A4DE237BBFQ35842756-47CE341A-3CFC-4675-BD85-9378C4C55996Q35857273-912D22D6-03C3-4596-9A62-CE91D06FAE84Q35870592-A19B213D-4563-45BF-B2C7-5BA022B4A4BFQ36588064-69BBD339-F290-4613-BAB9-DB93C49BC99FQ36612929-27C6D8A2-4368-4B97-86E9-473A7EC4A39AQ36698306-C67B9EA4-BC47-44C6-9C8F-3407AF9B1A49Q36739363-5B2E6BA5-B615-467B-9662-09B9B8EB535AQ36780156-D8001AA8-8AA7-4762-BF06-C105D5A8E1DEQ36970552-E34B4734-C11F-46A7-8C2A-4529BC10428FQ38586294-9F3FACB5-235D-4F49-B2EA-99FEC4CB7CE7Q38823264-9ADAF78A-6805-4DE5-8A43-DBF027D676EAQ39302482-1571034B-8554-45F8-B262-B1B5DAB0E5CDQ40391705-5018E2C5-B32F-4D11-A2E1-962FC1C3F2F4Q44106019-E843C1E0-5CA2-4AC2-83B1-BD6F37030705Q46768300-B6CEDE59-D670-4443-A1CC-EF3119A75EAEQ47244680-CC7375A0-C09F-4990-88AF-FCA9761E46F1Q52723914-B48AB591-F77F-4458-9523-65AAB3BA8977Q56576756-E132077E-509D-4EFB-B6D8-E846CF3AAA95Q56763096-20B3B057-6E1B-48A8-B310-8EB023D16E83Q56909960-F213FE13-7855-424C-B0BE-26545C305318Q59268041-822A86F4-5144-4FC3-97F8-68784E2CE551
P2860
A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins
@nl
A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.
@ast
A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.
@en
type
label
A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins
@nl
A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.
@ast
A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.
@en
prefLabel
A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins
@nl
A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.
@ast
A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.
@en
P2093
P2860
P1433
P1476
A recombinant Yellow Fever 17D vaccine expressing Lassa virus glycoproteins.
@en
P2093
Anysha Ticer
Dmitry Moshkoff
Igor S Lukashevich
Ilia Tikhonov
Jean Patterson
Juan Zapata
Kathleen Brasky
Maria S Salvato
Peter J Bredenbeek
Phillippe Marianneau
P2860
P304
P356
10.1016/J.VIROL.2005.12.001
P407
P577
2006-01-18T00:00:00Z